Product Packing: 10X10
Product Composition: Trypsin 48 mg + Bromelain 90 mg + Rutoside 100 mg + Diclofenac 50 mg
Product Price: MRP : 2109.38
RUTWIN-D Tablets
contain Trypsin 48 mg, Bromelain 90 mg,
Rutoside 100 mg and Diclofenac 50 mg, combining proteolytic enzymes,
a flavonoid and a non-steroidal anti-inflammatory drug (NSAID) for selected
painful inflammatory conditions associated with swelling when treatment is
considered appropriate.
Trypsin and Bromelain are proteolytic enzymes used
for supportive anti-inflammatory and anti-edematous action, Rutoside is a
flavonoid with antioxidant and capillary-support properties, and Diclofenac
provides analgesic and anti-inflammatory action. This is a prescription
medicine and should be used only under qualified medical supervision.
Each tablet contains:
·
Trypsin - 48 mg
·
Bromelain - 90 mg
·
Rutoside - 100 mg + Diclofenac - 50 mg
Dosage form: Tablet
Pack size: 10 x 10 tablets
RUTWIN-D may be
prescribed in selected patients for painful inflammatory conditions associated
with swelling or tissue edema where the combination is considered appropriate.
·
Musculoskeletal pain associated with
inflammation and swelling
·
Post-traumatic pain, inflammation and
soft-tissue edema
·
Post-operative pain and swelling when
clinically appropriate
·
Orthopaedic inflammatory conditions where
combined NSAID and enzyme-flavonoid support is considered suitable
The product should be used only on medical
advice and according to the approved label. Persistent, recurrent or severe
pain, swelling or inflammation requires medical evaluation.
RUTWIN-D combines
proteolytic enzymes and a flavonoid with an NSAID:
Trypsin:
A proteolytic enzyme used in enzyme-based formulations intended to support
resolution of inflammatory edema and tissue debris.
Bromelain: A mixture of proteolytic
enzymes derived from pineapple, used for supportive anti-inflammatory and
anti-edematous action in selected clinical settings.
Rutoside and
Diclofenac: Rutoside
provides antioxidant and capillary-support properties, while Diclofenac
inhibits cyclooxygenase-mediated prostaglandin production to reduce pain and
inflammation.
Dosage and Direction for Use
Use RUTWIN-D only
according to the approved product label and the prescription of a qualified
healthcare professional. Dose, timing and duration depend on the indication,
patient factors and applicable product instructions.
Swallow the tablet with water as directed.
Use the lowest effective dose for the shortest
duration prescribed; do not exceed the recommended dose.
Do not combine with other NSAIDs, analgesics or
enzyme-containing products unless specifically advised.
Possible Side Effects
As with other prescription medicines, unwanted
effects may occur. Seek medical advice if symptoms are persistent, severe or
unusual. Possible effects can include:
·
Indigestion, abdominal discomfort, nausea,
vomiting or diarrhoea
·
Headache, dizziness or other gastrointestinal
symptoms
·
Gastrointestinal irritation, ulceration or
bleeding associated with Diclofenac
·
Allergic or hypersensitivity reactions in
susceptible individuals
·
Serious gastrointestinal, kidney, liver,
cardiovascular, bleeding-related or severe skin/allergic reactions require
urgent medical attention.
Precautions and Contraindications
Before using RUTWIN-D,
relevant medical history, gastrointestinal and cardiovascular risk,
kidney/liver function, bleeding risk, allergies and concomitant medicines
should be reviewed. Important precautions include:
·
Do not use in patients with known
hypersensitivity to Trypsin, Bromelain, Rutoside, Diclofenac, other NSAIDs,
pineapple-derived products or formulation ingredients.
·
Patients with active or recurrent
gastrointestinal ulceration or bleeding require careful assessment and may have
contraindications to Diclofenac.
·
Use caution in kidney disease, liver disease,
dehydration, cardiovascular disease, hypertension, heart failure,
NSAID-sensitive asthma or a history of gastrointestinal disease.
·
Patients with bleeding disorders or those
taking anticoagulant or antiplatelet medicines require professional assessment
because of potential bleeding-related concerns.
·
Pregnancy and breastfeeding require
professional assessment. NSAIDs have important pregnancy-related restrictions,
particularly in later pregnancy.
·
Patients scheduled for surgery or invasive
procedures should inform their healthcare professional about all medicines and
enzyme products they use.
·
Keep out of reach of children and store
according to pack instructions, protected from excessive heat and moisture.
·
Diclofenac may interact with anticoagulants,
antiplatelet medicines, certain blood-pressure medicines, diuretics, lithium,
methotrexate and other NSAIDs. Trypsin and Bromelain may require additional
caution with medicines that affect blood clotting.
·
Do not start, stop or change regular medicines
while using RUTWIN-D without professional advice.
RUTWIN-D offers pharmaceutical distributors and healthcare
entrepreneurs an opportunity to add a Trypsin 48 mg
+ Bromelain 90 mg + Rutoside 100 mg + Diclofenac 50 mg tablet
to their orthopaedic and pain-management portfolio.
Pain and inflammation associated with swelling
represent an established therapeutic segment. Responsible promotion of RUTWIN-D
should remain consistent with approved product information, prescription status
and applicable regulations.
·
Combination of proteolytic enzymes, Rutoside
and Diclofenac
·
Trypsin 48 mg + Bromelain 90 mg + Rutoside 100
mg + Diclofenac 50 mg formulation
·
Convenient tablet dosage form
·
Suitable addition to orthopaedic, surgical and
pain-management portfolios
·
Potential for ethical promotion through
appropriate healthcare channels
·
Opportunity for territory-based pharmaceutical
distribution
Ethics Medinova Private
Limited offers PCD Pharma Franchise opportunities for RUTWIN-D in selected
territories across India, subject to availability, applicable regulations and
mutually agreed business terms.
Franchise partners may benefit from the company’s
product portfolio, promotional support, supply coordination and business
assistance.
·
Monopoly-based territory opportunities,
subject to availability
·
Promotional materials and visual aids
·
Product information and marketing support
·
Reliable supply coordination
·
Access to a growing pharmaceutical product
portfolio
·
Professional partner assistance
Partner with Ethics
Medinova to explore PCD Pharma Franchise opportunities for RUTWIN-D and other quality-focused
healthcare products.
Ethics Medinova also supports businesses
exploring third-party manufacturing of Trypsin
48 mg + Bromelain 90 mg + Rutoside 100 mg + Diclofenac 50 mg Tablets under
their own brand, subject to applicable licensing, regulatory and manufacturing
requirements.
Our third-party manufacturing support may include:
·
Customized product and pack requirements,
subject to regulatory feasibility
·
Private-label manufacturing opportunities
·
Customized packaging and branding support
·
Product label and pack configuration
assistance
·
Manufacturing coordination through suitable
licensed facilities
·
Support for documentation and applicable
regulatory requirements
This service may be suitable for
pharmaceutical companies, healthcare brands, startups and entrepreneurs seeking
to expand an orthopaedic, surgical or pain-management portfolio.
RUTWIN-D is a tablet formulation containing
Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg and Diclofenac 50 mg, combining
enzyme-flavonoid support with NSAID analgesic and anti-inflammatory action.
It may be prescribed for selected painful
inflammatory conditions associated with swelling or tissue edema, subject to
the approved product label and clinical assessment.
Take RUTWIN-D exactly as prescribed or
according to the approved product label. Do not exceed the prescribed dose or
duration.
Duration should follow the approved label and
medical advice. Diclofenac-related gastrointestinal, kidney and cardiovascular
risks may increase with prolonged exposure, so treatment should generally use
the lowest effective dose for the shortest appropriate duration.
Yes. Particular caution may be needed with
anticoagulants, antiplatelet medicines, other NSAIDs and several other
medicines. Patients should provide their complete medicine list to the
prescriber.
People with gastrointestinal ulcer or bleeding
history, cardiovascular disease, kidney or liver disease, hypertension,
bleeding disorders, planned surgery, pregnancy or breastfeeding, allergies, or
regular medicines require professional assessment.
Yes. Ethics Medinova offers PCD Pharma
Franchise opportunities for selected products and territories, subject to
availability and mutually agreed terms.
Businesses interested in Trypsin 48 mg + Bromelain 90 mg + Rutoside 100 mg +
Diclofenac 50 mg Tablets may explore third-party manufacturing and
private-label support with Ethics Medinova, subject to
applicable regulatory and prescription-drug requirements.
RUTWIN-D product information in this
document is for general and professional business information. Exact
indications, dosage, duration, contraindications, warnings, interactions,
excipients and regulatory status should be verified against the current
approved product label before prescribing, dispensing, use or promotion. This
document is not a substitute for professional medical advice.
